



New Claims

- ✓ 34. A composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said composition is packaged with instructions directing use of the composition as an anti-inflammatory agent.
- ✓ 35. The composition of claim 34, wherein the cocoa procyanidin is a dimer.
36. The composition of claim 34, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
- ✓ 37. The composition of claim 34 further comprising a pharmaceutically acceptable carrier.
- ✓ 38. The composition of claim 34 further comprising a veterinary acceptable carrier.
- ✓ 39. The composition of claim 34 further comprising a food science carrier.
40. The composition of claim 34, which is a dietary supplement.
41. The packaged composition of claim 34 further comprising a cyclo-oxygenase modulator.
42. The packaged composition of claim 41, wherein the cyclo-oxygenase modulator is a non-steroidal anti-inflammatory drug.
43. The packaged composition of claim 42, wherein the non-steroidal anti-inflammatory drug is an aspirin.
- ✓ 44. A composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said composition is packaged with instructions directing use of the composition as an antiplatelet therapy.
- ✓ 45. The composition of claim 44, wherein the cocoa procyanidin is a dimer.
- ✓ 46. The composition of claim 44, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
- ✓ 47. The composition of claim 44 further comprising a pharmaceutically acceptable carrier.
- ✓ 48. The composition of claim 44 further comprising a veterinary acceptable carrier.
- ✓ 49. The composition of claim 44 further comprising a food science carrier.
50. The composition of claim 44, which is a dietary supplement. N
51. The packaged composition of claim 44 further comprising a cyclo-oxygenase modulator.
52. The packaged composition of claim 51, wherein the cyclo-oxygenase modulator is a non-steroidal anti-inflammatory drug.

53. The packaged composition of claim 52, wherein the non-steroidal anti-inflammatory drug is an aspirin.

54. A composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said composition is packaged with instructions directing use of the composition as an agent for improving or maintaining vascular health.

55. The composition of claim 54, wherein the cocoa procyanidin is a dimer.

56. The composition of claim 54, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.

57. The composition of claim 54 further comprising a pharmaceutically acceptable carrier.

58. The composition of claim 54 further comprising a veterinary acceptable carrier.

59. The composition of claim 54 further comprising a food science carrier.

60. The composition of claim 54, which is a dietary supplement.

61. A composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said composition is packaged with instructions directing use of the composition for at least one of the following: modulating nitric oxide synthesis, inducing vasodilation, modulating renal function, and reducing blood pressure.

62. The composition of claim 61, wherein the cocoa procyanidin is a dimer.

63. The composition of claim 61, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.

64. The composition of claim 61 further comprising a pharmaceutically acceptable carrier.





65. The composition of claim 61 further comprising a veterinary acceptable carrier.


66. The composition of claim 61 further comprising a food science carrier.


67. The composition of claim 61, which is a dietary supplement.

68. A composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said composition is packaged with instructions directing use of the composition for at least one of the following: treating hypertension, inhibiting LDL oxidation, reducing platelet aggregation, inhibiting monocyte adhesion, inhibiting vascular smooth muscle proliferation, reducing the risk of thrombosis, treating or preventing atherosclerosis, and treating or preventing restenosis.

69. The composition of claim 68, wherein the cocoa procyanidin is a dimer.

- 
70. The composition of claim 68, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
71. The composition of claim 68 further comprising a pharmaceutically acceptable carrier.
72. The composition of claim 68 further comprising a veterinary acceptable carrier.
73. The composition of claim 68 further comprising a food science carrier.
74. The composition of claim 68, which is a dietary supplement.
75. A composition comprising a cocoa procyanidin monomer and/or oligomer in admixture with a cyclo-oxygenase modulator.
76. The composition of claim 75, wherein the cyclo-oxygenase modulator is a non-steroidal anti-inflammatory drug.
77. The composition of claim 76, wherein the non-steroidal anti-inflammatory drug is an aspirin.
78. The composition of claim 75, wherein the cocoa procyanidin is a dimer.
79. A method of modulating nitric oxide synthesis by administering to a subject in need thereof a composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said subject is a human or a veterinary animal.
80. The method of claim 79, wherein the subject is a human.
81. The method of claim 80, wherein the human is at risk of arteriosclerosis, thrombosis, heart attack, stroke or vascular circulation problems.
82. The method of claim 80, wherein the human is suffering from atherosclerosis.
83. The method of claim 79, wherein the cocoa procyanidin is a dimer.
84. The method of claim 79, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
85. The method of claim 80 further comprising a pharmaceutically acceptable carrier.
86. The method of claim 79 further comprising a food science carrier.
87. A method of treating hypertension by administering a composition comprising a cocoa procyanidin monomer and/or oligomer to a subject suffering from hypertension, wherein said subject is a human or a veterinary animal.
88. The method of claim 87, wherein said subject is a human.
89. The method of claim 87, wherein the cocoa procyanidin is a dimer.
- 
- 
- 

- 
90. The method of claim 87, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
91. The method of claim 88 further comprising a pharmaceutically acceptable carrier.
92. The method of claim 87 further comprising a food science carrier.
93. A method of anti-platelet therapy or prophylaxis comprising administering to a subject in need thereof a composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said subject is a human or a veterinary animal.
94. The method of claim 93, wherein said subject is a human.
95. The method of claim 93, wherein the cocoa procyanidin is a dimer.
96. The method of claim 93, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
97. The method of claim 94 further comprising a pharmaceutically acceptable carrier.
98. The method of claim 93 further comprising a food science carrier.
99. The method of claim 93 further comprising administering to the subject a cyclo-oxygenase modulator.
100. The method of claim 99, wherein the cyclo-oxygenase modulator is a non-steroidal anti-inflammatory drug.
101. The method of claim 100, wherein the non-steroidal anti-inflammatory drug is an aspirin.
102. A method of treating, reducing the risk of, or preventing atherosclerosis, thrombosis, restenosis, heart attack or stroke comprising administering to a subject in need thereof a composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said subject is a human or a veterinary animal.
103. The method of claim 102, wherein said subject is a human.
104. The method of claim 102, wherein the cocoa procyanidin is a dimer.
105. The method of claim 102, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
106. The method of claim 103 further comprising a pharmaceutically acceptable carrier.
107. The method of claim 102 further comprising a food science carrier.
108. The method of claim 102 further comprising administering to the subject a cyclo-oxygenase modulator.

- 
109. The method of claim 108, wherein the cyclo-oxygenase modulator is a non-steroidal anti-inflammatory drug.
110. The method of claim 109, wherein the non-steroidal anti-inflammatory drug is an aspirin.
111. A method of treating, reducing the progression of, or preventing a condition associated with inflammation comprising administering to a subject in need thereof a composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said subject is a human or a veterinary animal.
112. The method of claim 111, wherein said subject is a human.
113. The method of claim 112, wherein the condition associated with inflammation is at least one of the following: inflammatory bowel disease, ulcerative colitis, Chron's disease, gingivitis, periodontal disease, acute edema, chronic arthritis, and spondylitis.
114. The method of claim 111, wherein the cocoa procyanidin is a dimer.
115. The method of claim 111, wherein the cocoa procyanidin is at least one of oligomers 3-12 or any mixture thereof.
116. The method of claim 112 further comprising a pharmaceutically acceptable carrier.
117. The method of claim 111 further comprising a food science carrier.
118. A method of inhibiting lipoxxygenase activity comprising administering to a subject a composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said subject is a human or a veterinary animal.
119. A method of modulating oxidative stress to prevent associated inflammatory disorders and vascular diseases comprising administering to a subject a composition comprising a cocoa procyanidin monomer and/or oligomer, wherein said subject is a human or a veterinary animal.
-